ArticleInfectious agents and cancer2026
Anti-Epstein-Barr virus (EBV) antibodies in EBV-associated gastric carcinoma.
Article in Infectious agents and cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAbout 10% of gastric carcinomas (GC) harbor monoclonal Epstein-Barr virus (EBV). Anti-EBV antibody profiles distinguished patients with EBV-associated GC (EBVaGC) from those with EBV-negative GC (EBVnGC) in a previous study. Therefore, we examined these markers in a larger cohort with patient samples from Japan, a high gastric cancer-risk population.
methodsMulti-microbial Nucleic Acid Programmable Protein Array was used to test stored sera from 102 EBVaGC and 131 EBVnGC patients.
resultsAmong 89 IgG antibodies against EBV-specific antigens, 32 (36%) showed at least 10% seroprevalence in either EBVaGC or EBVnGC patients. Seropositivity of ten anti-EBV antibodies (LF2, BDLF2, BXLF1, BRLF1, BKRF3, BHRF1, BORF2, BZLF1, BNRF1, and BALF2) were significantly higher in EBVaGC patients than those with EBVnGC, with a maximal odds ratio of 22 (95% confidence interval: 5.2, 195) for anti-LF2. The ten antibodies collectively had an area under the receiver operating curve of 0.747 (95% CI: 0.683, 0.811). Five of these markers (LF2, BRLF1, BXLF1, BORF2, and BALF2) were among the seven discriminatory antibodies identified in the previous study. These differences in serological reactions were seen for proteins in the lytic infection phase, but not for those in the latent infection phase, consistent with the previous results.
conclusionThe present study confirms the utility of anti-EBV serology for non-invasive detection of EBVaGC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.